Sid Bhoopathy, COO of Absorption Systems, Selected as a Philadelphia Business Journal "40 Under 40" Award Winner

Published: Apr 19, 2013

EXTON, Pa., April 18, 2013 /PRNewswire/ -- Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that its Chief Operating Officer, Sid Bhoopathy, Ph.D., has been selected as one of the Philadelphia Business Journal's "40 Under 40" Award winners. The awards, co-sponsored by First Financial Group and the Fox Business School of Temple University, will be presented at a ceremony on Wednesday, May 22nd at the Crystal Tea Room in Philadelphia.

"This award is a reflection of the hard work and dedication of the outstanding people I work with," said Dr. Bhoopathy. "I'm proud that we have achieved so much together, and happy that their success is being recognized in this way. And it's an honor to represent the Philadelphia region when I travel all over the world on behalf of Absorption Systems." Since joining Absorption Systems in 2004, Dr. Bhoopathy has held various positions of steadily increasing responsibility, culminating in his being named COO in 2011. His unique mix of business acumen and scientific sophistication have enabled him to make critical contributions to every aspect of the company's operations and its steady growth year after year. In addition, he is a highly sought-after speaker on the Biopharmaceutics Classification System, a pathway in which Absorption Systems is the world leader.

Serving more than 250 different customers annually throughout the globe, and over 110 employees based in facilities in Exton, PA, San Diego, CA, and Panama City, Panama, Absorption Systems is a global leader in contract research for the life sciences industry. With a clear vision of the future and an unwavering commitment to innovation, the company is poised for even stronger growth going forward.

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, in San Diego, CA, and in Panama, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit

Chris Bode, Ph.D.

VP Scientific & Corporate Communications

Absorption Systems


Back to news